Search Results - "Jogdand, Harsh"

Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants by Vadrevu, Krishna Mohan, Ganneru, Brunda, Reddy, Siddharth, Jogdand, Harsh, Raju, Dugyala, Sapkal, Gajanan, Yadav, Pragya, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar Vivek, Gillurkar, Chandra Sekhar, Kushwaha, Jitendra Singh, Mohapatra, Satyajit, Bhate, Amit, Rai, Sanjay Kumar, Ella, Raches, Abraham, Priya, Prasad, Sai, Ella, Krishna

“…This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against ancestral and Variants of Concern (VOCs) up to 12 months. It is well known…”
Get full text

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation by Ganneru, Brunda, Jogdand, Harsh, Daram, Vijaya Kumar, Das, Dipankar, Molugu, Narasimha Reddy, Prasad, Sai D., Kannappa, Srinivas V., Ella, Krishna M., Ravikrishnan, Rajaram, Awasthi, Amit, Jose, Jomy, Rao, Panduranga, Kumar, Deepak, Ella, Raches, Abraham, Priya, Yadav, Pragya D., Sapkal, Gajanan N., Shete-Aich, Anita, Desphande, Gururaj, Mohandas, Sreelekshmy, Basu, Atanu, Gupta, Nivedita, Vadrevu, Krishna Mohan

“…We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum…”
Get full text

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial by Ella, Raches, Vadrevu, Krishna Mohan, Jogdand, Harsh, Prasad, Sai, Reddy, Siddharth, Sarangi, Vamshi, Ganneru, Brunda, Sapkal, Gajanan, Yadav, Pragya, Abraham, Priya, Panda, Samiran, Gupta, Nivedita, Reddy, Prabhakar, Verma, Savita, Kumar Rai, Sanjay, Singh, Chandramani, Redkar, Sagar Vivek, Gillurkar, Chandra Sekhar, Kushwaha, Jitendra Singh, Mohapatra, Satyajit, Rao, Venkat, Guleria, Randeep, Ella, Krishna, Bhargava, Balram

“…To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor…”
Get full text

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial by Ella, Raches, Reddy, Siddharth, Jogdand, Harsh, Sarangi, Vamshi, Ganneru, Brunda, Prasad, Sai, Das, Dipankar, Raju, Dugyala, Praturi, Usha, Sapkal, Gajanan, Yadav, Pragya, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar Vivek, Gillurkar, Chandra Sekhar, Kushwaha, Jitendra Singh, Mohapatra, Satyajit, Bhate, Amit, Rai, Sanjay, Panda, Samiran, Abraham, Priya, Gupta, Nivedita, Ella, Krishna, Bhargava, Balram, Vadrevu, Krishna Mohan

“…BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum…”
Get full text

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study by Vadrevu, Krishna Mohan, Reddy, Siddharth, Jogdand, Harsh, Ganneru, Brunda, Mirza, Nizam, Tripathy, Virendra Nath, Singh, Chandramani, Khalatkar, Vasant, Prasanth, Siddaiah, Rai, Sanjay, Ella, Raches, Blackwelder, William, Prasad, Sai, Ella, Krishna

“…Despite having milder symptoms than adults, children are still susceptible to and can transmit SARS-CoV-2. Vaccination across all age groups is therefore…”
Get full text